Cardiol Therapeutics Inc. (CRDL) stock
CRDLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.86−0.02 (-2.28%)
Close on Nov 20, 2026Market cap $86.48MP/E –Yield –
Cardiol Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
For fiscal 2025 it was -C$23.88M. The highest annual figure on record is -C$9.17M in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -C$23.88M | – |
| FY2024 | Dec 31, 2024 | -C$25.08M | – |
| FY2023 | Dec 31, 2023 | -C$25.24M | – |
| FY2022 | Dec 31, 2022 | -C$27.30M | – |
| FY2021 | Dec 31, 2021 | -C$23.55M | – |
| FY2020 | Dec 31, 2020 | -C$9.17M | – |
See a number that looks wrong?